About Rocky Mountain Cancer Centers
For 30 years, Rocky Mountain Cancer Centers (RMCC) has been a leader in delivering world-class cancer care to patients across the Colorado Front Range. Our dedicated team of cancer treatment specialists are relentlessly dedicated to our patients’ health. We fight alongside each patient, providing personalized treatment plans and partnering with their referring physicians. We listen and learn and treat every patient with the utmost sensitivity and kindness to deliver the absolute best care possible. This strategic and compassionate approach to cancer care promotes optimal patient outcomes and survivorship through evidence-based measures.
RMCC was formed in 1992, when a group of independent medical oncology practices joined together to become a network of community-based clinic sites. Today, we are a physician-led and owned practice that provides coordinated and comprehensive care at 19 locations across the state. Our board-certified oncologists are masters in their fields, specializing in specific cancer types and blood disorders. They are recognized by their industry peers for their knowledge, skills, and drive to exceed expectations every step of the way.
About The US Oncology Network
RMCC is a practice in The US Oncology Network (The Network). This collaboration unites the practice with more than 1,400 independent physicians dedicated to delivering value-based, integrated care to patients — close to home. Through The Network, these independent doctors come together to form a community of shared expertise and resources dedicated to advancing local cancer care and to delivering better patient outcomes. The Network is supported by McKesson Corporation, whose coordinated resources and infrastructure allow doctors in The Network to focus on the health of their patients, while McKesson focuses on the health of their practices.
RMCC also participates in clinical trials through Sarah Cannon Research Institute (SCRI), a joint venture with US Oncology Research and one of the world’s leading oncology research organizations conducting community-based clinical trials. Focused on advancing therapies for patients over the last three decades, SCRI is a leader in drug development. It has conducted more than 600 first-in-human clinical trials since its inception and contributed to pivotal research that has led to the majority of new cancer therapies approved by the FDA today. RMCC has played a role in more than 100-FDA approved cancer therapies and earned the “Highest Accruing Site Award” from US Oncology Research for having more than 1,900 patients in clinical trials. Together, we are able to offer the most advanced, nationally vetted treatments available and access to more clinical trials than any other cancer facility in Colorado.
American College of Radiology (ACR) for Positron Emission Tomography (PET) and Computed Tomography (CT)